Dr. Nahal R. Lalefar
Claim this profileUCSF Benioff Children's Hospital Oakland
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
4 reported clinical trials
12 drugs studied
Area of expertise
1Leukemia
Stage II
Stage I
NGS-MRD negative
2Lymphoblastic Leukemia-Lymphoma
Stage II
Stage I
NGS-MRD negative
Affiliated Hospitals
Clinical Trials Nahal R. Lalefar is currently running
Non-TBI Conditioning
for HCT in Acute Lymphoblastic Leukemia
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be followed in an observational cohort (HCT center standard of care).
Recruiting1 award Phase 2
IST + BMT
for Aplastic Anemia
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a secondary treatment in patients who did not get better with IST, had their disease come back, or a new worse disease replaced it (like leukemia). This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat SAA. The trial will also assess whether health-related quality of life and early markers of fertility differ between those randomized to URD BMT or IST, as well as assess the presence of marrow failure-related genes and presence of gene mutations associated with MDS or leukemia and the change in gene signatures after treatment in both study arms. This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard for treatment of SAA.
Recruiting2 awards Phase 3
More about Nahal R. Lalefar
Clinical Trial Related6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Nahal R. Lalefar has experience with
- Matched Unrelated Donor Hematopoietic Cell Transplantation (MUD-HCT)
- Haploidentical Hematopoietic Cell Transplantation (haploHCT)
- Letermovir
- Methotrexate
- Rabbit Anti-Thymocyte Globulin (ATG)
- Horse Anti-Thymocyte Globulin (ATG)
Breakdown of trials Nahal R. Lalefar has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Acute Disease
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nahal R. Lalefar specialize in?
Nahal R. Lalefar focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved Stage II patients, or patients who are Stage I.
Is Nahal R. Lalefar currently recruiting for clinical trials?
Yes, Nahal R. Lalefar is currently recruiting for 4 clinical trials in Oakland California. If you're interested in participating, you should apply.
Are there any treatments that Nahal R. Lalefar has studied deeply?
Yes, Nahal R. Lalefar has studied treatments such as matched unrelated donor hematopoietic cell transplantation (MUD-HCT), Haploidentical hematopoietic cell transplantation (haploHCT), Letermovir.
What is the best way to schedule an appointment with Nahal R. Lalefar?
Apply for one of the trials that Nahal R. Lalefar is conducting.
What is the office address of Nahal R. Lalefar?
The office of Nahal R. Lalefar is located at: UCSF Benioff Children's Hospital Oakland, Oakland, California 94609 United States. This is the address for their practice at the UCSF Benioff Children's Hospital Oakland.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.